(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: 0 166 937
A2

(12) EUROPEAN PATENT APPLICATION

(21) Application number: 85106209.1

(22) Date of filing: 21.05.85

(51) Int. Cl.⁴: C 07 D 233/22
C 07 D 239/06, C 07 D 239/26
C 07 C 123/00, A 61 K 31/415
A 61 K 31/505, C 07 D 405/04

(30) Priority: 06.06.84 US 617770

(43) Date of publication of application:
08.01.86 Bulletin 86/2

(84) Designated Contracting States:
BE CH DE FR GB IT LI NL SE

(71) Applicant: ABBOTT LABORATORIES
14th Street and Sheridan Road North St
North Chicago Illinois 60064(US)

(72) Inventor: DeBernardis, John Francis
35 Burnett Avenue
Lake Villa, IL 60046(US)

(72) Inventor: Basha, Fatima Zehra
232 Bayshore Drive
Lake Bluff, IL 60044(US)

(74) Representative: Modiano, Guido et al,
MODIANO, JOSIF, PISANTY & STAUB Modiano &
Associati Via Meravigli, 16
I-20123 Milan(IT)

(54) Adrenergic compounds.

(57) Disclosed herein are adrenergic compounds represented by the formula



wherein m is 0, 1 or 2; R_1, R_2, R_3 are taken from the group consisting of hydrogen, hydroxy, loweralkyl, loweralkoxy, halo, or $NHSO_2R$ wherein R is taken from the group consisting of hydrogen, loweralkyl or arylalkyl, provided that R_1, R_2, R_3 cannot simultaneously be hydrogen, and provided that when one of R_1, R_2, R_3 is halo, the other two cannot simultaneously be hydrogen; R_1 and R_2 or R_2 and R_3 taken together can form a methylenedioxy or ethylenedioxy bridge; and R_4 and R_5 are hydrogen or taken together form a closed ring of the formula



wherein n is 1 or 2, and the dashed line represents a single or double bond when n is 1, and R_6 is taken from the group consisting of hydrogen, loweralkyl, or arylalkyl, and the pharmaceutically acceptable salts thereof.

EP 0 166 937 A2